Acadia, like any pharma, would want to maximise revenue from trof during its patent protection period. A few years to go there. Once trof runs its course for retts, that's when you want to renew the patent, slightly change the molecular structure to go under another patent exclusivity period, or bring in 2591. There is no reason for them to rush into 2591 for retts. That's the pharma game. Matters little to them if 2591 is better or not.
Ann: DAYBUE (trofinetide) 2024 net sales US$348 million, page-33
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$13.10 |
Change
-0.800(5.76%) |
Mkt cap ! $1.629B | |||
| Open | High | Low | Value | Volume |
| $13.95 | $13.96 | $12.88 | $9.534M | 725.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 266 | $13.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.15 | 1619 | 2 |
View Market Depth
| Last trade - 16.10pm 13/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |